CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
January 2017—Thermo Fisher Scientific’s two Clariom brand of assays, Clariom D Pico and Clariom S Pico, are designed primarily for translational researchers to accelerate the discovery and validation of complex biomarker signatures derived from coding and noncoding RNA across the whole transcriptome. Based on industry-leading microarray technology, the Clariom Pico assay designs include up-to-date content curated from a large number of public sequence databases, including RefSeq, Noncode, Ensembl, VEGA, lncRNAWiki, and RNA Central, among others.
For a deep view of the transcriptome, Clariom D Pico assays allow rapid discovery of coding and noncoding genes, exons, and splicing events, including rare transcripts, expanding the potential to find novel biomarkers missed by alternative techniques. For researchers interested in a gene-level view of all well-annotated genes across the transcriptome, Clariom S Pico assays enable scientists to quickly and easily identify important expression changes in genes and pathways.
The assays can extract data from as little as 100 pg of total RNA from a wide range of common and challenging sample types, including formalin-fixed, paraffin-embedded tissues and whole blood, without the need for globin mRNA reduction or rRNA removal. When paired with Thermo Fisher’s Transcriptome Analysis Console (TAC) software, scientists can independently go from sample to insights in three days.
The assays are for research use only, not for use in diagnostic procedures.
Thermo Fisher Scientific, 800-766-7000